Few medical treatments have generated as much confusion as hormone replacement therapy (HRT). Some women have heard that hormone therapy is dangerous and should be avoided entirely. Others believe every woman should take hormones indefinitely. Neither perspective reflects the current scientific evidence.
Modern menopausal hormone therapy has evolved substantially over the past two decades. Large clinical trials, improved understanding of hormone physiology, newer medication formulations, and updated recommendations from leading medical societies have transformed how physicians approach treatment.
Today, most experts agree on an important principle: hormone therapy is neither appropriate for every woman nor inappropriate for every woman. Instead, treatment should be individualized after careful consideration of symptoms, age, timing of menopause, medical history, cardiovascular risk, breast cancer risk, and patient preferences.
At LiteWell, hormone replacement therapy is viewed as one component of comprehensive midlife health care. We focus not only on symptom relief but also on preserving muscle mass, metabolic health, bone density, cardiovascular wellness, sleep quality, cognitive function, and overall quality of life.
Key Takeaways
- Menopausal hormone therapy remains the most effective treatment for moderate-to-severe vasomotor symptoms, including hot flashes and night sweats.
- Current evidence differs substantially from the public perception created after the original Women’s Health Initiative (WHI) reports.
- Treatment decisions should be individualized based on age, time since menopause, symptoms, medical history, and personal risk factors.
- FDA-approved hormone therapies and appropriately prescribed bioidentical hormones both have roles in clinical practice, but they are not interchangeable terms.
- Hormone therapy is only one component of healthy aging and should be combined with nutrition, resistance training, sleep optimization, and preventive medical care.
Table of Contents
- What Is Hormone Replacement Therapy?
- Why Hormone Levels Change
- Which Hormones Are Replaced?
- Benefits of Hormone Therapy
- Potential Risks
- FDA-Approved vs. Compounded Bioidentical Hormones
- Current Medical Guidelines
- Who May Be a Candidate?
- Myths vs. Facts
- Frequently Asked Questions
- LiteWell’s Clinical Perspective
- References
What Is Hormone Replacement Therapy?
Hormone Replacement Therapy (HRT)—more accurately referred to by many medical organizations as Menopausal Hormone Therapy (MHT)—uses prescription hormones to treat symptoms caused by declining ovarian hormone production during perimenopause and menopause.
The primary goals of treatment include:
- Reducing hot flashes
- Improving sleep
- Reducing night sweats
- Improving quality of life
- Supporting vaginal and urinary health
- Helping preserve bone density
- Improving sexual health in appropriate patients
For selected women, therapy may also improve brain fog, mood, joint discomfort, energy, physical function, and overall well-being. Importantly, hormone therapy is not intended to reverse aging or guarantee improvements in every symptom experienced during midlife.
Why Hormone Levels Change
Women are born with a finite number of ovarian follicles. Over time, ovarian function gradually declines. As menopause approaches, ovulation becomes less predictable, progesterone production declines, estrogen levels fluctuate widely before ultimately falling, and testosterone production gradually decreases with age.
These hormonal changes affect tissues throughout the body because hormone receptors are present in the brain, bones, blood vessels, skin, muscles, joints, vaginal tissue, urinary tract, heart, and adipose tissue. This explains why menopause influences far more than reproductive health.
Which Hormones Are Replaced?
Although numerous hormones contribute to female physiology, menopausal hormone therapy most commonly involves one or more of the following three primary hormones.
Estrogen
Estrogen remains the cornerstone of menopausal hormone therapy. It is the most effective treatment for hot flashes, night sweats, vaginal dryness, and genitourinary syndrome of menopause (GSM). Estrogen also plays important roles in bone remodeling, blood vessel function, skin elasticity, brain function, sleep regulation, and connective tissue health. Declining estrogen contributes to many of the hallmark symptoms of menopause.
Progesterone
Progesterone serves two distinct purposes. First, it may improve sleep quality for some women. Second, for women who still have a uterus, progesterone is generally prescribed alongside systemic estrogen to protect the uterine lining (endometrium) from estrogen-induced overgrowth, which can increase the risk of endometrial hyperplasia and cancer if estrogen is used alone. Women who have undergone a hysterectomy may not require progesterone, although treatment decisions remain individualized.
Testosterone
Women naturally produce testosterone throughout life, primarily from the ovaries and adrenal glands. Although levels are much lower than in men, testosterone contributes to sexual desire, sexual arousal, lean muscle mass, bone health, physical performance, and motivation. Current evidence supports testosterone therapy primarily for carefully selected postmenopausal women with hypoactive sexual desire disorder (HSDD) after appropriate evaluation. Routine testosterone therapy for fatigue, weight loss, anti-aging, or cognitive enhancement remains less well supported by current evidence.
How Hormone Therapy Is Administered
Hormones may be delivered using several different routes. The choice depends on symptoms, medical history, patient preference, and clinical goals.
Oral tablets are familiar and convenient but involve first-pass metabolism through the liver and effects on clotting factors.
Transdermal patches deliver estrogen through the skin directly into the bloodstream, offering stable hormone levels, avoidance of first-pass hepatic metabolism, and potentially lower risk of some thromboembolic complications compared with oral estrogen in appropriate patients. Many professional societies favor transdermal estrogen for women with certain cardiovascular risk factors.
Topical gels and sprays also provide systemic estrogen absorption while avoiding first-pass liver metabolism.
Vaginal estrogen primarily treats vaginal dryness, pain with intercourse, urinary symptoms, and recurrent urinary tract infections related to menopause. Because systemic absorption is minimal with many low-dose preparations, treatment considerations differ from systemic estrogen therapy.
Micronized progesterone has become increasingly popular because of its favorable side-effect profile and evidence supporting sleep benefits in some women.
Benefits of Hormone Therapy
Hormone therapy is not appropriate solely because hormone levels decline. Treatment is considered because evidence demonstrates meaningful benefits for selected women.
Relief of Vasomotor Symptoms
Systemic estrogen remains the most effective treatment for hot flashes, night sweats, and heat intolerance. Many women experience substantial improvement within several weeks. Improved symptom control frequently leads to better sleep, improved daytime energy, improved work performance, and better overall quality of life.
Improved Sleep
Sleep disruption is one of the most common complaints during perimenopause and menopause. Hormone therapy may improve sleep indirectly by reducing night sweats, frequent awakenings, and temperature instability. For selected women, micronized progesterone may also contribute to improved sleep quality. Because sleep influences nearly every aspect of health, improving sleep often has downstream benefits for mood, energy, cognitive function, and metabolic health.
Genitourinary Syndrome of Menopause (GSM)
Declining estrogen frequently affects vaginal tissue, vulvar tissue, the urethra, and the bladder. Symptoms may include vaginal dryness, pain with intercourse, urinary urgency, recurrent urinary tract infections, burning, and irritation. Low-dose vaginal estrogen therapy remains one of the most effective treatments for GSM and differs from systemic hormone therapy in both absorption and clinical considerations.
Bone Health
Estrogen plays a central role in maintaining bone remodeling. Following menopause, bone loss accelerates. Appropriately prescribed systemic estrogen helps reduce bone turnover and lowers the risk of osteoporotic fractures while treatment continues. Additional measures include resistance training, weight-bearing exercise, adequate dietary protein, calcium intake when appropriate, and vitamin D when indicated.
Quality of Life
For women with moderate-to-severe menopausal symptoms, hormone therapy may improve daily functioning, exercise capacity, mood, sexual health, social participation, and overall quality of life. The decision to begin therapy should consider both objective medical risks and the significant impact symptoms may have on day-to-day living.
Potential Risks
Every medical treatment involves potential risks. The goal is not eliminating risk entirely—it is selecting treatments whose expected benefits outweigh potential harms for an individual patient. Potential risks vary depending upon age, overall health, route of administration, medication formulation, dose, and personal and family medical history.
Venous Thromboembolism (Blood Clots)
Systemic estrogen—particularly oral formulations—may increase the risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). The absolute risk remains low for many healthy women beginning therapy near menopause. Several studies suggest transdermal estrogen may have a lower effect on clotting factors than oral estrogen, although treatment decisions should always be individualized.
Stroke
Stroke risk increases with age regardless of hormone therapy. For younger women beginning treatment near menopause, the absolute increase in stroke risk appears small. However, age, smoking, hypertension, migraine with aura, atrial fibrillation, and other cardiovascular risk factors must be considered before prescribing systemic estrogen.
Breast Cancer
Breast cancer remains one of the most discussed aspects of hormone therapy. Current evidence is more nuanced than early public messaging suggested. Important considerations include type of hormone used, duration of therapy, whether progesterone accompanies estrogen, individual baseline breast cancer risk, family history, and personal history of breast disease. For many women without significant risk factors, short- to intermediate-term hormone therapy does not produce the level of risk once widely feared. Routine breast cancer screening should continue according to established guidelines.
Endometrial Cancer
Women who retain their uterus generally require progesterone when systemic estrogen is prescribed. Unopposed estrogen stimulates the uterine lining and increases the risk of endometrial hyperplasia and endometrial cancer. Appropriate progesterone substantially reduces this risk. Women who have undergone hysterectomy often do not require progesterone, although exceptions exist.
Cardiovascular Disease
The relationship between hormone therapy and cardiovascular disease depends heavily upon timing. Beginning therapy close to menopause appears fundamentally different from initiating treatment decades later. Current guidelines emphasize careful cardiovascular risk assessment before treatment begins. Hormone therapy should not be prescribed solely to prevent heart disease.
Dementia
Current evidence does not support prescribing menopausal hormone therapy specifically to prevent dementia. Although some women experience improvement in cognitive symptoms such as brain fog when vasomotor symptoms and sleep improve, hormone therapy should not be considered an established treatment for neurodegenerative disease.
The Women’s Health Initiative: Context and Evolution
No discussion of hormone replacement therapy is complete without addressing the Women’s Health Initiative (WHI). Published in 2002, the WHI dramatically changed menopause care worldwide. Millions of women discontinued hormone therapy almost overnight. Physicians became understandably cautious.
The WHI primarily evaluated oral conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA) in a population with an average participant age of approximately 63 years—more than a decade beyond the average age of menopause. Many participants already had established cardiovascular risk factors.
Subsequent analyses have demonstrated that risk varies considerably depending upon age, time since menopause, type of hormone used, dose, route of administration, and individual medical history. This concept has become known as the timing hypothesis: women who begin menopausal hormone therapy before age 60 or within approximately 10 years of menopause generally have a more favorable benefit-risk profile than women initiating therapy later in life.
FDA-Approved vs. Compounded Bioidentical Hormones
One of the greatest sources of confusion involves the term “bioidentical hormones.” Bioidentical simply means the hormone has the same molecular structure as hormones naturally produced by the human body. Importantly, many FDA-approved hormone products are bioidentical—including FDA-approved formulations of estradiol and micronized progesterone. This distinction is often overlooked.
Compounded hormone therapy is prepared by licensed compounding pharmacies to meet an individual patient’s needs, such as alternative dosages, different delivery systems, or allergy-related formulation changes. Compounded products may be appropriate in selected clinical situations. However, unlike FDA-approved medications, compounded hormone products are not reviewed by the FDA for safety, effectiveness, or manufacturing consistency before they are dispensed. For this reason, major medical organizations generally recommend FDA-approved products whenever an appropriate commercially available option exists.
Current Medical Guidelines
Several leading organizations have updated their guidance over the past decade, including The North American Menopause Society (NAMS), the American College of Obstetricians and Gynecologists (ACOG), the Endocrine Society, and the International Menopause Society (IMS).
Although wording differs, there is broad agreement on several principles:
- Menopausal hormone therapy remains the most effective treatment for vasomotor symptoms.
- Treatment should be individualized.
- The lowest effective dose should be used to achieve therapeutic goals.
- Therapy should be reassessed periodically.
- Benefits and risks should be reviewed through shared decision-making.
Who May Be a Candidate?
Systemic hormone therapy may not be appropriate for every woman. Potential contraindications include, but are not limited to:
- Known or suspected estrogen-sensitive breast cancer
- Unexplained vaginal bleeding
- Active liver disease
- Active or recent venous thromboembolism
- Recent stroke
- Recent myocardial infarction
- Known thrombophilia in certain circumstances
These conditions require individualized evaluation and often consultation with the patient’s broader medical team. Hormone therapy should be reassessed periodically, with updates to symptom review, blood pressure, weight and body composition, medication tolerance, breast cancer screening, bone health evaluation, and cardiovascular risk assessment.
Myths vs. Facts
Myth: Hormone therapy is dangerous for every woman.
Fact: Hormone therapy has risks, but those risks are not identical for every patient. Age, time since menopause, formulation, route of administration, dose, treatment duration, and personal medical history all affect the benefit-risk profile. For many healthy symptomatic women who begin therapy near menopause, treatment may offer meaningful symptom relief with an acceptable level of risk after individualized evaluation.
Myth: Every woman should take hormone therapy.
Fact: Many women experience mild symptoms and do not need medical treatment. Others prefer nonhormonal options or have medical histories that make systemic hormone therapy inappropriate. Treatment should respond to the patient’s symptoms, health risks, and preferences—not to a universal rule.
Myth: The Women’s Health Initiative proved that HRT causes heart disease and breast cancer in all women.
Fact: The Women’s Health Initiative provided essential information, but its findings were frequently generalized beyond the population and formulations studied. Participants were, on average, substantially older than women who commonly begin treatment for menopausal symptoms. Subsequent analyses have emphasized differences related to age, treatment timing, and hormone formulation. Modern recommendations favor individualized interpretation rather than applying one trial result uniformly to every woman.
Myth: Compounded hormones are safer because they are natural.
Fact: The term “natural” does not establish safety, effectiveness, purity, or manufacturing consistency. Compounded hormone products are not FDA-approved and may have variable potency or pharmacokinetics. Major professional organizations generally favor FDA-approved formulations when a suitable approved product is available.
Myth: Hormone therapy prevents all age-related disease.
Fact: Hormone therapy should not be prescribed as a universal anti-aging treatment or solely to prevent cardiovascular disease, dementia, or every chronic condition associated with aging. Its clearest established roles are treating menopausal symptoms and helping prevent bone loss in appropriately selected patients.
Myth: Hormone therapy must automatically stop at age 65.
Fact: There is no universal rule requiring every woman to stop treatment at a specific age. Continued therapy may be considered for persistent symptoms after periodic reassessment and informed discussion of risks and benefits.
Myth: Hormone levels must be repeatedly measured to adjust treatment.
Fact: For typical menopausal care, symptom response and clinical safety are generally more useful than repeatedly targeting serum hormone levels. Testing may still be appropriate when the diagnosis is uncertain, symptoms are atypical, or another endocrine condition is suspected.
Frequently Asked Questions About Hormone Replacement Therapy
Q: What is hormone replacement therapy?
Hormone replacement therapy, also called menopausal hormone therapy, uses prescription estrogen and, when needed, a progestogen to treat symptoms associated with declining ovarian hormone production. Systemic therapy may be used for hot flashes, night sweats, sleep disruption related to vasomotor symptoms, and broader menopausal symptom management. Local vaginal estrogen is primarily used for vaginal and urinary symptoms. Treatment is individualized according to symptoms, age, medical history, uterine status, risk factors, and patient preference.
Q: What symptoms can hormone therapy improve?
Systemic menopausal hormone therapy is most effective for vasomotor symptoms such as hot flashes and night sweats. It may also improve sleep when sleep disruption is driven by nighttime symptoms. Local or systemic estrogen may improve vaginal dryness, painful intercourse, and genitourinary syndrome of menopause. Systemic therapy also helps prevent bone loss while treatment continues. Some women report improvements in mood, joint discomfort, brain fog, or overall well-being, but these responses vary and should not be guaranteed.
Q: Who is generally considered a favorable candidate for menopausal hormone therapy?
A favorable candidate is often a healthy woman with bothersome menopausal symptoms who is younger than 60 or within approximately 10 years of menopause and who does not have a major contraindication. This is not an absolute rule. Treatment decisions should account for symptom severity, cardiovascular risk, clotting history, cancer history, uterine status, and patient preferences.
Q: Who should generally avoid systemic hormone therapy?
Systemic therapy may be inappropriate for women with certain histories, including: known or suspected estrogen-sensitive cancer, unexplained vaginal bleeding, active or recent venous thromboembolism, recent stroke or myocardial infarction, active liver disease, and certain inherited clotting disorders. This list is not exhaustive. Complex cases may require coordination with gynecology, oncology, cardiology, hematology, or another specialist.
Q: Do I need progesterone if I take estrogen?
A woman with an intact uterus generally needs an appropriate progestogen when using systemic estrogen. This protects the uterine lining from excessive estrogen stimulation. A woman who has had a hysterectomy may often use estrogen without progesterone, although the final regimen depends on surgical and medical history.
Q: Is transdermal estrogen safer than oral estrogen?
Transdermal estrogen avoids first-pass metabolism through the liver and appears to have less effect on some clotting pathways than oral estrogen. It is frequently considered for women with certain metabolic or thromboembolic risk factors. However, “safer” depends on the patient and the outcome being considered. Route selection should be individualized rather than treated as a universal rule.
Q: Does hormone therapy cause breast cancer?
The relationship is more complex than a yes-or-no answer. Risk appears to differ according to: estrogen-only versus combined treatment, progestogen type, duration, baseline breast-cancer risk, age, and prior breast history. Some combined estrogen-progestogen regimens are associated with increased breast-cancer risk over time, while estrogen-only therapy has shown a different risk pattern in major trials. Decisions should therefore be individualized and accompanied by routine breast screening.
Q: Does hormone therapy prevent heart disease?
Hormone therapy should not be prescribed solely for cardiovascular-disease prevention. However, the cardiovascular effects appear to vary according to age and timing. Women beginning therapy closer to menopause generally have a more favorable profile than women initiating treatment many years later. Cardiovascular risk assessment remains an essential part of treatment planning.
Q: Does hormone therapy prevent dementia?
Hormone therapy is not currently recommended solely to prevent dementia. Some women experience better mental clarity when sleep and vasomotor symptoms improve, but that is different from preventing Alzheimer disease or another neurodegenerative disorder. Initiating systemic hormone therapy at an older age for dementia prevention is not supported by current evidence.
Q: What does “bioidentical hormone therapy” mean?
A bioidentical hormone has the same molecular structure as a hormone produced by the human body. FDA-approved estradiol and micronized progesterone are bioidentical. Therefore, bioidentical does not automatically mean compounded. Patients should ask whether a product is: FDA-approved, commercially manufactured, compounded for an individualized need, and supported by appropriate safety and efficacy data.
Q: When are compounded hormones appropriate?
Compounded hormones may be considered when a patient has a legitimate clinical need that cannot be met by an available FDA-approved product, such as an allergy to an inactive ingredient or a required dosage form that is not commercially available. They should not automatically be considered safer, more natural, or more effective than FDA-approved therapy.
Q: Do I need hormone testing before starting HRT?
Routine hormone testing is generally not required to treat typical menopause symptoms. During perimenopause, hormone levels fluctuate considerably, so a single test may not accurately reflect a woman’s overall hormonal state. Testing may be appropriate when menopause occurs unusually early, the diagnosis is uncertain, menstrual changes may have another cause, or another endocrine disorder is suspected.
Q: How long can a woman remain on hormone therapy?
There is no universal treatment duration. Some women use therapy for several years during the most symptomatic period. Others continue longer because symptoms persist or because the individual benefit remains meaningful. Treatment should be reassessed periodically, with continued shared decision-making regarding symptoms, risks, dose, route, and alternatives.
Q: Can hormone therapy help with weight gain?
Hormone therapy is not a weight-loss treatment. Menopause is associated with changes in body-fat distribution, muscle mass, sleep, and insulin sensitivity. Treating significant symptoms may help some women sleep better, exercise more consistently, and function better, but sustainable body-composition improvement still requires nutrition, resistance training, physical activity, and metabolic-risk management.
Q: What is the first step at LiteWell?
Women begin with a Free Medical Fit Call to determine whether LiteWell’s physician-supervised women’s hormone program may align with their needs. Those who proceed complete a Premier Discovery Intake, where symptoms, menstrual and reproductive history, medical risks, lifestyle, relevant laboratory information, treatment preferences, and alternatives are reviewed before an individualized plan is developed. Hormone therapy is never prescribed automatically.
LiteWell’s Clinical Perspective
At LiteWell, we believe hormone replacement therapy should be neither reflexively prescribed nor reflexively dismissed. For decades, women have received contradictory messages. Some were told that menopause symptoms were simply part of aging and should be endured. Others encountered clinics presenting hormones as a universal solution for fatigue, weight gain, low mood, poor sleep, or cognitive change. Both approaches are incomplete.
Menopausal hormone therapy is a medical treatment with meaningful potential benefits, known limitations, and risks that vary substantially among patients. The central question is not whether hormone therapy is universally “good” or “bad.” The appropriate question is: does the anticipated benefit of hormone therapy outweigh the potential risk for this individual woman, using this formulation, at this dose, through this route, at this stage of life?
Current guidance supports individualized decision-making. Systemic hormone therapy remains the most effective treatment for bothersome vasomotor symptoms, and it can help prevent bone loss while treatment continues. The benefit-risk profile is generally more favorable for healthy women who begin treatment before age 60 or within approximately 10 years of menopause, provided they do not have significant contraindications.
At LiteWell, our evaluation may include:
- The nature and severity of menopausal symptoms
- Age and time since the final menstrual period
- Menstrual, reproductive, and surgical history
- Personal and family history of breast cancer
- Cardiovascular and thromboembolic risk
- Unexplained vaginal bleeding
- Bone health
- Sleep quality
- Sexual and urinary symptoms
- Metabolic health and body composition
- Current medications
- Patient goals and treatment preferences
Treatment is then individualized. Some women may benefit primarily from systemic estrogen, with appropriate endometrial protection if the uterus remains present. Others may need only local vaginal therapy for genitourinary symptoms. Some may prefer or require nonhormonal treatment.
Hormone therapy is also placed within a broader midlife health strategy that includes resistance training, adequate protein intake, cardiovascular exercise, healthy sleep, blood-pressure management, metabolic-risk assessment, bone-health screening, routine cancer screening, tobacco avoidance, and ongoing medical follow-up. Hormones may improve symptoms and function—they do not replace the foundations of healthy aging.
Ready to find out if hormone therapy is right for you? Schedule a Free Medical Fit Call with LiteWell today. Our physician-supervised program begins with a thorough Premier Discovery Intake—no automatic prescriptions, no one-size-fits-all protocols. Just individualized care built around your health, your symptoms, and your goals.
Clinical Pearls
The formulation matters. “Hormone therapy” is not one single treatment. Clinical effects and risks may differ according to estrogen type, progestogen type, oral versus transdermal delivery, systemic versus local therapy, dose, duration, patient age, and medical history. A risk estimate associated with one formulation should not automatically be applied to every hormone product.
Timing matters. Starting hormone therapy near the menopausal transition is clinically different from initiating systemic therapy for the first time decades after menopause. Age and time since menopause should be incorporated into every benefit-risk discussion.
A uterus generally requires protection. Systemic estrogen stimulates the endometrium. For a woman with an intact uterus, an appropriate progestogen is generally added to reduce the risk of endometrial hyperplasia and cancer. Women without a uterus may often use estrogen alone, depending on individual history.
“Bioidentical” does not mean compounded. FDA-approved estradiol and micronized progesterone are bioidentical hormones because their molecular structures match endogenous human hormones. Compounded therapy is a separate concept. Compounded products may be appropriate when an individual patient has a need that cannot be met by an FDA-approved product, but they are not evaluated by the FDA for potency, consistency, safety, and effectiveness in the same manner.
Symptoms—not arbitrary hormone targets—guide most treatment. Routine hormone-level testing is generally not required before treating typical menopausal symptoms. Hormone concentrations fluctuate considerably during the menopausal transition, and treatment is usually adjusted according to clinical response rather than an arbitrary serum target.
Related LiteWell Services
- HRT for Women
- Longevity & Performance Medicine
- Medical Weight Loss
- Free Medical Fit Call
- Premier Discovery Intake
- Optimize Phase
- Maintenance Phase
- Hybrid Care Model
References
- The Menopause Society. 2022 Hormone Therapy Position Statement.
- American College of Obstetricians and Gynecologists. Hormone Therapy for Menopause.
- American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy.
- Endocrine Society. Treatment of Symptoms of the Menopause: Clinical Practice Guideline.
- Endocrine Society. Hormone Therapy in Menopause.
- U.S. Food and Drug Administration. Hormone Replacement Therapies Can Help Women With Bothersome Menopausal Symptoms.
- Women’s Health Initiative randomized-trial and long-term follow-up publications.
- Peer-reviewed reviews and trials published in Menopause, JAMA, The New England Journal of Medicine, The Lancet, and The Journal of Clinical Endocrinology & Metabolism.
Medical Disclaimer: This article is intended for educational purposes only and does not constitute individualized medical advice. Menopausal hormone therapy has potential benefits, risks, contraindications, and alternatives that must be evaluated for each patient. Treatment should be prescribed and monitored by a licensed clinician familiar with the patient’s medical history, symptoms, medications, cancer risk, cardiovascular risk, thromboembolic risk, uterine status, and treatment goals. No specific symptom improvement or health outcome is guaranteed. LiteWell does not provide emergency medical care.
Medication and Regulatory Disclosure: LiteWell’s women’s hormone programs may include FDA-approved prescription hormone therapies when clinically appropriate and prescribed following medical evaluation. Compounded hormone products may be considered in selected circumstances when a clinician determines that a patient has a legitimate medical need that cannot be met by an appropriate commercially available FDA-approved product. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, quality, potency, or manufacturing consistency in the same manner as approved drugs. Medication selection is individualized through shared decision-making. No treatment is prescribed automatically, and no specific outcome is guaranteed.
